- Home
- FIS vs ALNY Comparison
FIS vs ALNY Comparison
Compare FIS & ALNY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | FIS | ALNY |
|---|---|---|
| Founded | 1968 | 2002 |
| Country | United States | United States |
| Employees | N/A | 115 |
| Industry | Business Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0B | 39.0B |
| IPO Year | 2001 | 2004 |
Fundamental Metrics
Financial Performance| Metric | FIS | ALNY |
|---|---|---|
| Price | $38.95 | $286.68 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 14 | 28 |
| Target Price | $72.23 | ★ $471.00 |
| AVG Volume (30 Days) | ★ 5.8M | 919.2K |
| Earning Date | 05-08-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.81% | N/A |
| EPS Growth | N/A | ★ 206.88 |
| EPS | ★ 4.58 | 2.33 |
| Revenue | ★ $10,677,000,000.00 | $1,037,418,000.00 |
| Revenue This Year | $30.41 | $52.67 |
| Revenue Next Year | $4.76 | $31.48 |
| P/E Ratio | ★ $8.56 | $121.39 |
| Revenue Growth | 5.43 | ★ 22.88 |
| 52 Week Low | $37.91 | $281.77 |
| 52 Week High | $82.74 | $495.55 |
Technical Indicators
Market Signals| Indicator | FIS | ALNY |
|---|---|---|
| Relative Strength Index (RSI) | 35.51 | 42.43 |
| Support Level | N/A | $284.69 |
| Resistance Level | $68.08 | $314.04 |
| Average True Range (ATR) | 1.39 | 10.17 |
| MACD | -0.19 | -0.74 |
| Stochastic Oscillator | 17.15 | 14.57 |
Price Performance
Historical ComparisonAbout FIS Fidelity National Information Services Inc.
Fidelity National Information Services provides core processing and ancillary services to banks, but its business has expanded over time. By acquiring SunGard in 2015, the company now provides record-keeping and other services to investment firms. With the acquisition of Worldpay in 2019, FIS was providing payment processing services for merchants and holding leading positions in the United States and United Kingdom. But the company sold off a majority interest in Worldpay and now has only a minority stake.
About ALNY Alnylam Pharmaceuticals Inc.
Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam's commercial RNAi therapeutic products include Onpattro and Amvuttra (for hATTR amyloidosis), Givlaari (for acute hepatic porphyria), and Oxlumo (for primary hyperoxaluria type 1), all developed and commercialized by Alnylam. Plus, Leqvio (for hypercholesterolemia) and Qfitlia (for hemophilia A or B), which are being commercialized by Alnylam's partners, Novartis and Sanofi, respectively. It also has several clinical programs across various therapeutic areas, including cardio-metabolic diseases, neuroscience, and hematology.